References
- Behre H M, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated, and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994; 40: 341–9
- Meikle A W, Arver S, Dobs A S, et al. Prostate size in hypogonadal men treated with a non-scrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191–6
- Behre H M, von Eckardstein S, Kliesch S, et al. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol 1999; 50: 629–35
- Wallace E M, Pye S D, Wild S R, et al. Prostate-specific antigen, and prostate gland size in men receiving exogenous testosterone for male contraception. Int J Androl 1993; 16: 35–40
- Frick J, Jungwirth A, Rovan E. Androgens, and the prostate. Testosterone: Action, Deficiency, Substitution 2nd edn, E Nieschlag, H M Behre. Springer, Berlin 1998; 259–91
- Ruijter E, van de Kaa C, Miller G, et al. Molecular genetics, and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22–45
- López-Otín C, Diamandis E P. Breast, and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998; 19: 365–96
- Chan J M, Stampfer M J, Giovannucci E, et al. Plasma insulin-like growth factor-I, and prostate cancer risk: a prospective study. Science 1998; 279: 563–6
- Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18: 847–53
- Heikkilä R, Aho K, Heliövaara M, et al. Serum testosterone, and sex hormone-binding globulin concentrations, and the risk of prostate carcinoma: a longitudinal study. Cancer 1999; 86: 312–15
- Morgentaler A, Bruning C O, 3rd, De Wolf W C. Occult prostate cancer in men with low serum testosterone levels. J Am Med Assoc 1996; 276: 1904–6
- Curran M J, Bihrle W, 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53: 423–4
- Orwoll E S, Klein R F. Osteoporosis in men. Endocr Rev 1995; 16: 87–116
- Jackson J A, Riggs M W, Spiekerman A M. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992; 304: 4–8
- Cooper C, Melton L J, III. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992; 3: 224–9
- Behre H M, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386–90
- Cauley J A, Seeley D G, Ensrud K, et al. Estrogen replacement therapy, and fractures in older women. Ann Intern Med 1995; 122: 9–16
- Leifke E, Körner H-C, Link T M, et al. Effects of testosterone replacement therapy on cortical, and trabecular bone mineral density, vertebral body area, and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998; 138: 51–8